Mankind Pharma Ltd - Asset Resilience Ratio

Latest as of September 2025: 8.83%

Mankind Pharma Ltd (MANKIND) has an Asset Resilience Ratio of 8.83% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Mankind Pharma Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

Rs25.45 Billion
≈ $275.27 Million USD Cash + Short-term Investments

Total Assets

Rs288.13 Billion
≈ $3.12 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Mankind Pharma Ltd's Asset Resilience Ratio has changed over time. See Mankind Pharma Ltd (MANKIND) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Mankind Pharma Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MANKIND market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs0.00 0%
Short-term Investments Rs25.45 Billion 8.83%
Total Liquid Assets Rs25.45 Billion 8.83%

Asset Resilience Insights

  • Limited Liquidity: Mankind Pharma Ltd maintains only 8.83% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Mankind Pharma Ltd Industry Peers by Asset Resilience Ratio

Compare Mankind Pharma Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
Drug Manufacturers - Specialty & Generic 43.05%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
Drug Manufacturers - Specialty & Generic 1.96%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Guobang Pharma Ltd
SHG:605507
Drug Manufacturers - Specialty & Generic 8.47%

Annual Asset Resilience Ratio for Mankind Pharma Ltd (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Mankind Pharma Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 6.09% Rs16.91 Billion
≈ $182.86 Million
Rs277.60 Billion
≈ $3.00 Billion
-0.15pp
2024-03-31 6.24% Rs7.46 Billion
≈ $80.72 Million
Rs119.63 Billion
≈ $1.29 Billion
-6.36pp
2023-03-31 12.60% Rs12.24 Billion
≈ $132.35 Million
Rs97.15 Billion
≈ $1.05 Billion
+1.92pp
2022-03-31 10.68% Rs9.77 Billion
≈ $105.63 Million
Rs91.48 Billion
≈ $989.29 Million
-18.15pp
2021-03-31 28.83% Rs18.37 Billion
≈ $198.70 Million
Rs63.73 Billion
≈ $689.18 Million
+11.91pp
2020-03-31 16.92% Rs8.58 Billion
≈ $92.82 Million
Rs50.73 Billion
≈ $548.66 Million
+16.32pp
2019-03-31 0.60% Rs246.21 Million
≈ $2.66 Million
Rs41.12 Billion
≈ $444.74 Million
--
pp = percentage points

About Mankind Pharma Ltd

NSE:MANKIND India Drug Manufacturers - Specialty & Generic
Market Cap
$10.03 Billion
Rs927.45 Billion INR
Market Cap Rank
#2227 Global
#87 in India
Share Price
Rs2246.70
Change (1 day)
-0.45%
52-Week Range
Rs1927.40 - Rs2696.50
All Time High
Rs2998.40
About

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory d… Read more